Recap: INVO Bioscience Q2 Earnings

  INVO Bioscience (NASDAQ:INVO) reported its Q2 earnings results on Monday, August 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

 

INVO Bioscience (NASDAQ:INVO) reported its Q2 earnings results on Monday, August 15, 2022 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

INVO Bioscience beat estimated earnings by 4.17%, reporting an EPS of $-0.23 versus an estimate of $-0.24.

Revenue was down $62 thousand from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.02 which was followed by a 0.96% drop in the share price the next day.

Here’s a look at INVO Bioscience’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.25 -0.22 -0.20 -0.19
EPS Actual -0.23 0.03 -0.24 -0.17
Revenue Estimate 240K 210K 330K 410K
Revenue Actual 162K 3.05M 218K 208K

To track all earnings releases for INVO Bioscience visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Lucid Announces Q3 Production & Deliveries, Sets Date For Q3 2023 Results; Lucid Produced 1,550 Vehicles During Q3, Plus Over 700 Additional Vehicles In Transit To Saudi Arabia For Final Assembly. The Company Delivered 1,457 Vehicles During The Same Pe…

Lucid Group, Inc. (NASDAQ:LCID), setting new standards for luxury electric experience with the Lucid Air, winner of the 2023 World Luxury Car Award, today announced production and delivery totals for the quarter ended September 30, 2023.

LCID